Impax In-Licenses US Commercial Rights to AstraZeneca’s Migraine Drug Zomig®
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 16 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1685 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Impax Laboratories has licensed US commercial rights to the tablet, orally disintegrating tablet and nasal spray formulations of AstraZeneca’s migraine drug Zomig® (zolmitriptan) for a total of US$130 M in quarterly payments plus tiered royalties on future sales...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS